Skip to main content
Biocure Technology Inc. logo

Biocure Technology Inc. — Investor Relations & Filings

Ticker · CURE.X LEI · 529900KSL59IBBDYBU95 CSE Manufacturing
Open in API
Filings indexed 149 across all filing types
Latest filing 2025-11-28 Management Reports
Country CA Canada
Listing CSE CURE.X

About Biocure Technology Inc.

https://biocuretech.com/

Biocure Technology Inc. is a biopharmaceutical company specializing in the development and commercialization of advanced biological medicines. The company's core focus areas include proprietary CAR T-cell therapies designed to treat various cancers, such as leukemia, lung, and breast cancer. Concurrently, Biocure is engaged in the development and commercialization of major biosimilar pharmaceutical products, aiming to improve the accessibility of complex biological treatments. Furthermore, the company pursues novel, highly-efficacious therapies for severe diseases caused by RNA viruses where significant unmet medical needs exist.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled 'Management’s Discussion & Analysis' (MD&A) for Biocure Technology Inc. as of September 30, 2025. It provides a detailed review of operations, financial position, and outlook, referencing National Instrument 51-102F1. It includes quarterly financial information and management's commentary on performance, which is the standard content for an MD&A report. While it discusses interim financial results, the document itself is the management's narrative analysis rather than the financial statements themselves. According to the filing definitions, this falls under the 'Management Reports' (MDA) category.
2025-11-28 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for the three and nine months ended September 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Comprehensive Loss, Statement of Changes in Shareholders' Equity, and Statement of Cash Flows) along with detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2025
2025-11-28 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for the period ended June 30, 2025. It contains comprehensive financial statements (Statement of Financial Position, Statement of Operations, Statement of Cash Flows, Statement of Changes in Equity) and detailed notes to the financial statements. It is not an announcement or a certification, but the actual interim financial report itself, fitting the definition of an Interim/Quarterly Report (IR). H2 2025
2025-08-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109 Venture Issuer Basic Certificate certifying the review of interim financial report and MD&A, but it does not contain the actual interim report or MD&A content itself. It is a regulatory certification form rather than the comprehensive Interim/Quarterly Report (IR) or Management Discussion and Analysis (MDA). It also is not merely announcing publication of a report (RPA), but is a regulatory filing required by securities legislation. Therefore it falls under the fallback category for general regulatory filings (RNS).
2025-08-26 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion & Analysis As at June 30, 2025” and consists of management’s narrative review of operations, financial position, results of operations, forward-looking statements, risk factors and business outlook, referencing the interim condensed financial statements. This matches the definition of a Management Reports (MDA) filing, which provides management’s detailed explanation of financial results, business trends and outlook. It is not the full interim report itself nor merely an announcement.
2025-08-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for Biocure Technology Inc. for the three and six months ended June 30, 2025. It contains detailed financial statements (Statement of Financial Position, Statement of Comprehensive Loss, Statement of Changes in Shareholders' Equity, Statement of Cash Flows) and extensive notes to the financial statements. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.